Skip to main content
. 2021 Oct 20;11:737989. doi: 10.3389/fonc.2021.737989

Table 1.

Study and patient characteristics of the included studies.

Author Year Study characteristics Patient characteristics
Country Study design Prevalence of PLNMs No. of extracted lymph node Reference standard No. of patients Age (median, range) PSA (median, range) D’Amico risk stratification
Frumer et al. (28) 2020 Israel Retro 13.5% Median 9
Range 6–14
PLND 89 67 (64–70) 8.5 (5–15) Intermediate 40; high risk 49
Franklin et al. (32) 2020 Australia Retro 24.5% Median 16
Range 1–53
PLND 233 68 (48–81) 7.4 (1.5–72.0) Low risk 2; intermediate 90; high risk 141
Kulkarni et al. (26) 2020 India Retro 45.7% NA PLND 35 NA NA Intermediate and high risk
Pallavi et al. (31) 2020 India Pro 24.1% NA NA 29 NA NA NA
Van Leeuwen et al. (24) 2019 Netherlands and Australia Retro 36.4% Median 16
Range 12–21
ePLND 140 NA 9.4 Intermediate 30; high risk 110
Yilmaz et al. (23) 2019 Turkey Retro 20.0% NA rPLND 10 NA NA Low risk 3; intermediate 15; high risk 6
Berger et al. (21) 2018 Australia Retro 4% Median 12
Range 3–22
PLND 50 649 ± 5.6 10.6 ± 8.1 NA
Gupta et al. (20) 2017 India Retro 58.3% Median 20 ePLND 12 61 (46–76) 24.3 (8.7–200.6) High risk 12
Zhang et al. (19) 2017 China Retro 35.7% Median 7
Range 2–15
PLND 42 69 (55–82) 37.25 (7.2–348.) Intermediate 17; high risk 25

NA, not available.